<?xml version="1.0" encoding="UTF-8"?>
<ref id="B24">
 <label>24.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Edelman</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Tacket</surname>
    <given-names>CO</given-names>
   </name>
   <name>
    <surname>Wasserman</surname>
    <given-names>SS</given-names>
   </name>
   <name>
    <surname>Bodison</surname>
    <given-names>SA</given-names>
   </name>
   <name>
    <surname>Perry</surname>
    <given-names>JG</given-names>
   </name>
   <name>
    <surname>Mangiafico</surname>
    <given-names>JA</given-names>
   </name>
  </person-group>. 
  <article-title>Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218</article-title>. 
  <source>Am J Trop Med Hyg</source>. (
  <year>2000</year>) 
  <volume>62</volume>:
  <fpage>681</fpage>â€“
  <lpage>5</lpage>. 
  <pub-id pub-id-type="doi">10.4269/ajtmh.2000.62.681</pub-id>
  <?supplied-pmid 11304054?>
  <pub-id pub-id-type="pmid">11304054</pub-id>
 </mixed-citation>
</ref>
